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ARTICLE
Patients with multiple sclerosis do not 
necessarily consume more alcohol or tobacco 
than the general population
Pacientes com esclerose múltipla não necessariamente consomem mais álcool ou tabaco 
do que a população geral
Yara Dadalti Fragoso1, Sidney Gomes2, Marcus Vinicius M. Goncalves3, Suzana C. Nunes Machado4, Rogerio 
de Rizo Morales5, Francisco Tomas M. de Oliveira2, João Filipe de Oliveira6, Neide R. Simoes Olmo1, Monica 
K. Fiuza Parolin7, Fabio Siquineli6, Patrick N. Stoney8
Multiple sclerosis (MS) is a lifelong inflammatory, demy-
elinating and degenerative disease of the central nervous 
system1. The disease typically starts in young adults who 
will often present depression2, fatigue3, anxiety4, anger5 and 
frustration in addition to hopelessness6. The combination of 
a chronic and disabling disease with this psychiatric profile 
suggests that patients with MS may be at risk of abuse of al-
cohol. In addition to compromising physical health, alcohol 
abuse has serious implications for mental health and cogni-
tive performance, conditions that are both already affected 
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AbstrACt
Purpose: Recent papers suggest that patients with multiple sclerosis (MS) are prone to alcohol misuse. This may be due to the combination 
of a lifelong and disabling disease with a psychiatric profile typical of MS. The objective of the present study was to assess these findings in 
a culturally different population of patients with MS. Method: The present case-control transversal study assessed 168 patients with MS 
and 168 control subjects from Brazil. results: There were no evidence that patients with MS drank more alcohol or, smoked more than did 
controls. In fact, control subjects had a significantly higher alcohol consumption. The only trait associated to higher alcohol consumption 
was anxiety, both for patients and controls. Conclusion: Unlike previous reports in the literature, patients with MS in our study did not drink 
or smoked more than a control population.
Keywords: multiple sclerosis, alcohol, tobacco, illicit drugs, anxiety, depression.
resuMo
Propósito: Artigos recentes sugerem que pacientes com esclerose múltipla (EM) tem tendência ao abuso de álcool. Isto poderia se dever 
à combinação de uma doença crônica e incapacitante e um perfil psiquiátrico típico da EM. O objetivo do presente estudo foi avaliar estes 
achados em uma população de pacientes com EM culturalmente diferente. Método: O presente estudo caso-controle transversal avaliou 
168 pacientes com EM e 168 controles, todos brasileiros. resultados: Não houve evidência que pacientes com EM usassem mais álcool 
ou tabaco do que os controles. Na verdade, os controles apresentavam um consumo significativamente maior de álcool. O único aspecto 
associado ao maior consumo de álcool foi a ansiedade, tanto para pacientes quanto para controles. Conclusão: Ao contrário de outros 
dados da literatura, pacientes com EM neste nosso estudo não bebem ou fumam mais do que a população controle.
Palavras-chave: esclerose múltipla, álcool, tabaco, ansiedade, depressão.
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by MS. Alcohol misuse may lead to decreased adherence 
to medical treatment7, which will also negatively affect the 
course of MS. Furthermore, alcohol consumption has been 
shown to have an inverse dose-dependent association with 
the risk of men and women developing MS8.
Data on alcohol and drug use among MS patients are rath-
er limited. A survey in the US database NARCOMS identified 
that, among nearly 9,000 patients, there was a high prevalence 
of adverse health behaviour9. This included smoking, high-risk 
alcohol intake, obesity and a sedentary lifestyle. In the few pa-
pers addressing the prevalence of alcohol misuse in MS cas-
es, consistent values between 14% and 22% have been report-
ed10,11,12,13. Despite the different methods used by these authors, 
the values are similar and, although high, they are not neces-
sarily different from those of the general population14. As for 
drug use among MS patients, the data are even more sparse, 
except with regard to cannabis with medicinal purposes13.
The present study addresses the issue of excessive drink-
ing and potential drug use among MS patients, using a 
case-control method to correct for population factors and 
cultural behaviour.
Method
This study was approved by the Ethics Committee of 
Universidade Metropolitana de Santos, SP, Brazil, under 
the registration number CAAE 37491014.5.0000.5509, in 
2014. Patients with MS attending outpatients consultations 
were invited to participate in this study in six MS units in 
Brazil. Control subjects matched for age, gender and socio-
economic status were included for each patient entering 
the trial. Control subjects were obtained from accompany-
ing carers of patients attending the outpatients service due 
to other diseases (not MS). These control subjects referred 
to be in good health and not undergoing any treatment for 
chronic illnesses. Socioeconomic level was assessed accord-
ing to the Brazilian Institute of Geography and Statistics 
(IBGE), which provides a scale varying from A1 to E in de-
creasing order of goods and possessions. All participants 
lived between latitude 18º 55’ 07” S and 27º 35’ 48” and lon-
gitude 46º 20’ 01” W and 49° 03’ 57” W. The study design was 
case-control and cross-sectional.
Each participant was individually interviewed using a set 
of questionnaires that investigated demographic data and 
also disease condition for those with MS. All participants 
were then screened for mood disorders using the Hospital 
Anxiety and Depression Scale (HAD)15. The consumption 
of alcohol was established using the Alcohol Use Disorder 
Identification Test (AUDIT scale)16. The patients’ neurolog-
ical disability was assessed using the expanded disability 
scale score (EDSS)17.
A brief description of the scales used for assessment in 
the present study is presented:
• HAD: This is a 14 item scale that scores 0 to 3 points for 
each item. There are seven items for depression and seven 
for anxiety and they are presented in a mixed format, i.e., 
items of depression alternating with items of anxiety. This 
scale does not allow for diagnoses of anxiety or depression, 
but it serves as a screening method for population studies.
• AUDIT: The questions are related to the alcohol con-
sumption in the past 12 months. There are 10 questions 
that score zero to four points, and the higher the con-
sumption of alcohol (and its consequences), the higher is 
the score value.
• EDSS: This is a disability scale, scoring from zero (nor-
mal) to 10 (death by the disease). It progresses with half 
points, and despite overvaluing gait and ambulation, it is 
the most used scale to assess MS disability.
Separate and direct questions regarding smoking (past or 
present) were also included at the end of the interview.
Statistical analysis on the data was carried out using 
GraphPad Prism. Two-way and one-way ANOVA, Spearman 
correlation, Kruskal-Wallis test, Mann-Whitney test and 
Student’s t-test were used to analyse the results. Significant 
values were those with p < 0.05. All data were blindly analysed 
by one of the authors who was not involved with any other 
stage of the project.
Results
Data were collected from 168 patients with MS and 168 
control subjects of the same gender and similar age, city, and 
socioeconomic level. There were no significant differences 
between these groups. In summary, there were 57 males and 
111 females, with a median age of 37 years in each group. The 
median score for the socioeconomic level was 25 for both 
groups. The classification system for socioeconomic level 
ranged from A1 (highest, 46 to 48 points) to E (lowest, zero 
to 7 points). A score of 25 represented the middle class B2.
Among the patients, there were 156 cases of 
relapsing-remitting MS (RRMS), nine cases of secondary pro-
gressive MS with relapses (SPMS) and three cases of primary 
progressive MS (PPMS). Only two patients were not using dis-
ease-modifying drugs (DMD). Seventy-four patients had not 
had any changes to their DMD, while 94 had undergone at 
least one change to their DMD. The average disease duration 
was 6.5 ± 4.6 years (range 1-30 years, median 5 years). The av-
erage EDSS was 1.3 ± 1.4 (range zero to 6.5).
There were 56 patients using glatiramer acetate 
(Copaxone®), 65 using interferon beta (23 Avonex®, 33 Rebif® 
and nine Betaferon®), 22 using natalizumab (Tysabri®) and 12 
using fingolimod (Gilenya®).
Patients with MS presented higher levels of depression 
(p = 0.001) than did controls. The same was not found for 
anxiety (p = 0.1).
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There were no significant differences in the use of tobac-
co between patients with MS and controls. However, when 
the use of alcohol was assessed, control subjects scored sig-
nificantly higher values on the AUDIT scale (p = 0.0001) than 
did patients with MS.
Fifty-five percent of the patients with MS scored zero on 
AUDIT (no use of alcohol at all), and only 3% scored seven or 
more points, which represents a strong likelihood of hazard-
ous or harmful alcohol consumption. On the other hand, only 
28% of the control subjects scored zero on AUDIT and 4.8% 
scored seven or more points. Only one control subject scored 
over 20 points, thus indicating alcohol dependence.
Regarding smoking, 23.3% of control subjects had a past 
or present history of cigarette smoking, with an average of 
12 cigarettes per day. Patients with MS had a similar past or 
present history of cigarette smoking (24.5%), but an average 
of only five cigarettes per day.
When subgroups of patients and controls were analysed, 
higher prevalence of alcohol intake was observed in those with 
anxiety in both groups alike (p = 0.03). There was no influence 
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Figure 1. Use of tobacco and alcohol by 168 patients with multiple sclerosis and 168 control subjects matched for gender, age and 
socioeconomic level. Control subjects drank more alcohol than patients with MS (p = 0.0001). No differences were observed in the 
use of tobacco.
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EDSS: expanded disability scale score; AUDIT: Alcohol Use Disorder Identification Test.
Figure 2. Correlation between disease duration and disability (assessed by EDSS) and the tobacco or alcohol use by 168 patients 
with multiple sclerosis (MS). Patients with higher degrees of disability drank less alcohol (p = 0.01). No other correlation was found.
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from age or gender on the use of alcohol, tobacco or illicit 
drugs in either of the groups. The presence of depression was 
correlated with higher use of alcohol (p = 0.04) among the con-
trol subjects, but this was not found among the patients.
Patients with MS and higher disability levels, as measured 
using EDSS, made significantly less use of alcohol (p = 0.01). 
Patients with higher disability had more depression than did 
patients with lower levels of EDSS values (p = 0.003). No spe-
cific DMD was correlated with higher use of alcohol or tobac-
co. Changes to DMD (which might be considered indicative 
of greater difficulty in achieving disease control) were not as-
sociated with the intake of alcohol or tobacco.
Age, gender and socioeconomic level were not correlated 
to alcohol intake or smoking for patients with MS or for con-
trol subjects.
Figures 1 to 5 summarize the above data. All p values are 
shown in the figures.
discussion
The present study did not confirm the findings of misuse 
of alcohol or tobacco by patients with MS. In fact, the control 
subjects made higher use of alcohol than did the patients and, 
when asked about alcohol during our interviews, many pa-
tients mentioned that “you are not supposed to drink if you 
have MS”. Our results are completely different from those 
found in the USA10,12,13 and Australia18, but our method was 
also different. While those studies comprised survey question-
naires sent to large populations of patients with MS, ours was 
a case-control study with individual interviews. It might be ar-
gued that patients could be inhibited from talking freely about 
unhealthy behavioural patterns during an interview but, in fact, 
their use of alcohol, drugs and smoking were already written 
in their medical records. The information was just confirmed 
and quantified during the interviews. A study on patients with 
MS in Canada11 who were individually interviewed also showed 
high alcohol intake, but that was not a case-control study. The 
number of patients involved in the studies was also different. 
In addition, it is possible that the recommendation to avoid al-
cohol intake while undergoing medical treatment might have 
positively influenced the health habits of the patients.
The patients with MS in the present study were mostly 
women, had low levels of disability, were relatively young and 
typically were not depressed. Relapsing-remitting MS was very 
frequent in this population of patients, the progressive forms 
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AUDIT: Alcohol Use Disorder Identification Test; HAD: Hospital Anxiety and Depression Scale.
Figure 3. Correlation of anxiety to the use of alcohol or tobacco in 168 patients with multiple sclerosis (MS) and 168 control 
subjects matched for gender, age and socioeconomic level. The alcohol consumption was positively correlated to anxiety for both 
patients (p = 0.02) and controls (p = 0.03).
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of MS being under-represented in our study. This is a typical 
finding in an outpatient environment, when patients with MS 
go for consultations and prescriptions on a regular basis. Those 
who are more limited or have progressive disease usually do 
not attend consultations and prefer homecare. Although these 
facts might have altered the results, no relationships were 
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Figure 4. Correlation of depression to the use of alcohol or tobacco in 168 patients with multiple sclerosis (MS) and 168 control 
subjects matched for gender, age and socioeconomic level. Smoking was significantly higher in control subjects only (p = 0.04).
found between gender, disability, age, depression and alcohol 
consumption. The only significant factor related to alcohol in-
take was the presence of anxiety, but this was not different be-
tween patients and controls. It is a well-known fact that anxi-
ety and alcohol-related disorders are comorbidities19,20 and this 
might explain the findings of the present study.
EDSS: expanded disability scale score; AUDIT: Alcohol Use Disorder Identification Test.
Figure 5. Correlation of disability levels (assessed by EDSS) with the use of alcohol, anxiety and depression by 168 patients with 
multiple sclerosis (MS). Patients with higher degrees of disability were significantly more depressed (p = 0.003). 
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Alcohol consumption was not correlated to a depressive 
mood. Even with the higher levels of depression among pa-
tients with MS than among controls, the correlation between 
depression and tobacco was found only among the controls. 
It must be stated that the HAD scale is not the ideal tool for 
assessing depression, being mostly used as a screening meth-
od for mood disorders. For the purpose of the present study, 
however, HAD was considered to suffice.
Regarding smoking, while many studies have confirmed 
the relationship between tobacco use and the risk of devel-
oping MS21, there are no studies concentrating on the preva-
lence of smoking among patients with the diagnosis of MS. 
In the present study, both patients and controls had similar 
frequencies of tobacco use, although the patients tended to 
smoke fewer cigarettes a day. Again, when asked about smok-
ing, most patients reported that “smoking was bad for MS” 
and they had cut down or stopped the habit.
The potential influence of cultural habits must be con-
sidered. Not only the methods used in the present study and 
the number of subjects were different, but the population also 
was also completely different from the North Americans or 
Australians studies. Attitudes towards alcohol or tobacco may 
differ among these countries and, while the present results are 
different from others, all results may be correct for their spe-
cific population. For example, Brazilian neurologists may have 
reinforced the concept that patients should avoid drinking al-
cohol due to the disease and the drugs they were using, and 
this may have affected the outcome in this population. These 
findings reinforce the fact that results from studies involving 
habits and lifestyle of one continent cannot simply be “trans-
planted” to patients from a different part of the world.
In conclusion, findings from studies on hazardous life-
style behaviour may reflect cultural influences. Results re-
lating to patients with MS cannot be extrapolated from one 
country or continent to another with the assumption that 
patients will have similar behaviour. At least for the popula-
tion of patients investigated in the present study, higher con-
sumption of alcohol or, tobacco was not confirmed.
